SEC Form 4 · accession 0001104659-26-080397
RHYTHM PHARMACEUTICALS, INC. · RYTM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alastair Garfield
Officer — Chief Scientific Officer
Period of report
Jul 1, 2026
Accepted (ET)
Jul 2, 2026 · 4:52 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001649904
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 1, 2026 | M | 4,445 | — | A | 12,208 | D | |
| Common Stock | Jul 1, 2026 | F | 2,150 | $110.41 | D | 10,058 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F3 | — | Jul 1, 2026 | M | 4,445 | D | — | — | Common Stock | 4,445 | 8,888 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- F2These shares were withheld for payment of the withholding taxes upon the vesting of the restricted stock units reported herein.
- F3The restricted stock units vest as to 25% of the total restricted stock units on each of the first four anniversaries of July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date.